Edmonton, Alberta, Canada, May 27, 2020 – PACYLEX PHARMACEUTICALS, INC. a pre-IND-stage pharmaceutical company targeting cancers with a new first-in-class therapeutic, announced today that its chief executive officer, Michael Weickert, will participate in the BIO 2020 conference being held virtually June 8-12, 2020. The company's chief medical officer, John Mackey MD will present a poster describing the Phase 1 program set to launch later this year at the ASCO 2020 conference being held virtually May 29-31, 2020. Additionally, Dr. Mackey and the company's chief science officer and principal founder, Luc Berthiaume, Ph.D., will present posters describing the therapeutic potential in breast cancer and lymphoma respectively at the AACR 2020 conference being held virtually June 22-24, 2020.
Despite the challenges of the COVID-19 pandemic, Pacylex is putting its scientific and business messages out at key virtual conferences in May and June.
Pacylex had an abstract accepted for presentation as a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting 2020. ASCO is an organization of nearly 45,000 oncology professionals united in a mission to conquer cancer through research, education, and promotion of the highest quality patient care. The annual meeting was originally planned for May 29-June 2 but due to the COVID-19 pandemic the meeting was converted to a virtual format being held on May 29-30. The Pacylex poster details are below.
Pacylex also had two abstracts accepted for presentation as posters at the American Association for Cancer Research (AACR) Annual Meeting 2020. The AACR is a 501c3 nonprofit whose mission is to prevent and cure cancer through research, education, communication, collaboration, funding, and advocacy. The annual meeting, which was to be held in April in San Diego, California, was first postponed until August then changed to a program delivered in two AACR Virtual Annual Meetings. Both Pacylex posters will be presented in Session II June 22-24.
In between these scientific conferences, Pacylex will participate in The Biotechnology Innovation Organization (BIO) 2020 International Convention scheduled for June 8-12. This will be an online platform instead of the planned meeting in San Diego. Pacylex CEO Michael Weickert is currently scheduling online meetings with investors and pharmaceutical companies and plans to update them on the progress towards the initiation of our first clinical trial with PCLX-001. Parties interested in discussions with Pacylex can reach out directly or through the BIO partnering system if also attending the virtual conference.
Pacylex is developing an oral small molecule drug, PCLX-001, to treat cancers low in N-myristoyltransferase 2 (NMT2), a myristoylation enzyme whose deficiency is associated with higher mortality in leukemia and lymphoma. The company’s results to date indicate that PCLX-001 selectively kills cancer cells and completely regresses (eliminates) tumors in animal models of acute myeloid leukemia (AML), diffuse large B-cell lymphoma (DLBCL) and Burkitt’s lymphoma (BL). PCLX-001 has also been shown to inhibit the growth of lung and breast cancer tumors in animal models. In tests using cultured cancer cells in vitro, PCLX-001 is at least ten times as potent as Ibrutinib (Imbruvica) and Dasatinib (Sprycel), two drugs currently used for hematologic malignancies. Pacylex completed GLP toxicology dosing in January and expects to file for regulatory authorization to commence clinical studies in 2020.
Pacylex is a pre-clinical pharmaceutical company targeting hematologic cancers with a new first-in-class therapeutic, and is headquartered in Edmonton, Alberta. Pacylex’s technology combines new insights from Dr. Luc Berthiaume of the University of Alberta, connecting myristoylation to cancer, with a family of high quality myristoylation inhibitors developed for African sleeping sickness by the University of Dundee Drug Discovery Unit in a program funded by Wellcome Trust. Pacylex licensed the molecules from the University of Dundee in 2015 to develop in oncology. PCLX-001 is the lead drug in a new class of NMT inhibitors, exploiting this new clinical target for cancer treatment. Pacylex plans to begin clinical studies of PCLX-001 in 2020 in diffuse large B-cell lymphoma and solid tumors. Pacylex is part of the Merck Invention Accelerator at TEC Edmonton.
For more information:
Michael J. Weickert
CEO, Pacylex Pharmaceuticals, Inc.
Twitter @ (https://twitter.com/pacylex)
#ASCO20, #AACR20, #BIODigital, #Pacylex